Abstracts tagged "Biomarkers"

Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…
Abstract Number: 0788 • ACR Convergence 2021
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Shahdi Malakooti¹, Brigid Wilson², Taissa Bej², Lenche Kostadinova³, Alyssa Lange², Megan O'Mara², David Zidar², Maya Mattar⁴ and Donald Anthony⁵, ¹Case Western Reserve University, UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ²VA Medical Center, Cleveland, OH, ³UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) correlates with disease activity in rheumatoid arthritis (RA) and is associated with subsequent mortality in non-RA patient…
Abstract Number: 1128 • ACR Convergence 2021
Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Liubov Arbeeva¹, Duncan Lascelles², Jordan Renner¹, Yvonne Golightly¹, Morten Karsdal³, Anne-Christine Bay-Jensen³ and Richard Loeser⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina State University, Raleigh, NC, ³Nordic Bioscience, Herlev, Denmark, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: To determine inter-relationships between blood-based collagen formation and degradation biomarkers and multiple joint osteoarthritis (MJOA) phenotypes in a community-based cohort.Methods: Data were from Johnston…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Nilasha Ghosh¹, Deanna Jannat-Khah², Karmela Kim Chan², Michael Postow³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Memorial Sloane Kettering Cancer Center, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 0213 • ACR Convergence 2021
Quantitative Assessment of Volumetric Change in Hip Effusion Using Artificial Intelligence in Patients with Osteoarthritis of the Hip
Jacob Jaremko¹, Banafshe Felfeliyan², Abhilash Hareendranathan¹, Bashiar Thejeel¹, Vanessa Quinn-Laurin¹, Mikkel Ostergaard³, Philip Conaghan⁴, Robert Lambert¹, Janet Ronsky² and Walter Maksymowych¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Accurate quantification of hip effusion volume may aid effective OA management as synovitis of the hip has been associated with pain and structural damage…
Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Marloes Verstappen¹, Hanna van Steenbergen², Pascal de Jong³ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden Univeristy Medical Center, Leiden, Netherlands, ³Erasmus MC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
Abstract Number: 1130 • ACR Convergence 2021
Osteoarthritis Patients Feel Their Tissue Remodeling
Anne-Christine Bay-Jensen¹, Yi He², Christian Thudium¹ and Morten Karsdal³, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Nordic Bioscience, Herlev
Background/Purpose: Osteoarthritis (OA) is a chronic disease characterized by pain and disability. Central to the revised FDA guidelines for the approval of a disease modifying…
Abstract Number: 1353 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
Dafna Gladman¹, Yihua Liu², Oh Kyu Yoon², Mona Trivedi², René Galien³, Robin Besuyen⁴, Vlad Malkov², Angie Hertz² and Vinod Chandran¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Gilead Sciences, Foster City, CA, ³Galapagos NV, Romainvulle, France, ⁴Galapagos BV, Leiden, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease characterized by musculoskeletal and skin inflammation. Selective inhibition of Janus kinase 1 (JAK1) has the…
Abstract Number: 1667 • ACR Convergence 2021
Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Yusuke Miwa¹, Yoshiaki Ohashi², Hajime Tomatsu³ and Yuko Mitamura⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²HMT Biomedical Inc., Yokohama, Japan, ³HMT Biomedical Inc., Chuo, Japan, ⁴Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: The odds of patients with rheumatoid arthritis (RA) experiencing depression is 1.42 (95% CI: 1.3–1.5; approximately 15% of patients) compared with healthy individuals. Diagnosis…
Abstract Number: 0281 • ACR Convergence 2021
Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis
Bryant England¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jill Poole¹, Joshua Baker³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) frequently complicates the rheumatoid arthritis (RA) disease course, leading to significant morbidity and premature mortality. RA-ILD may be underdiagnosed or…
Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Meshora Sthanithra², Christopher Toy², Anna Levesque², Lynn Fussner³, Alexa Meara³, Haikady Nagaraja², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol Langford⁷, Carol McAlear⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine Sreih¹², Kenneth Warrington¹³, Paul Monach¹⁴, Peter Merkel⁸, Brad Rovin³ and Dan Birmingham², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State university, Columbus, OH, ³Ohio State University Wexner Medical Center, Columbus, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic, Rochester, Minnesota, ¹⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
Abstract Number: 0800 • ACR Convergence 2021
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Stefano Alivernini¹, Simone Perniola², Marco Gessi³, Maria Rita Gigante⁴, Clara Di Mario⁵, Luca Petricca⁴, Dario Bruno⁵, Laura Bui¹, Annamaria Paglionico¹, Valentina Varriano¹, Maria Antonietta D'Agostino⁶, Barbara Tolusso¹ and Elisa Gremese⁷, ¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS - University of Verona, Santeramo in Colle, Italy, ³Fondazione PoliclinicoUniversitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].